Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Rabin Medical Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06951399CT.gov Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT05266846CT.gov Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK | — | Recruiting | — | — | — |
NCT05887492CT.gov Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT05797168CT.gov Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT05566223CT.gov CISH Inactivated TILs in the Treatment of NSCLC | — | Withdrawn | — | — | — |
NCT04533451CT.gov Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04682431CT.gov A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04691375CT.gov A Study of PY314 in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04027946CT.gov LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT03696212CT.gov Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma | — | Terminated | — | — | — |
Show 2 more trialsShow fewer
NCT03254004CT.gov Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm | — | Unknown | — | — | — |
NCT03184571CT.gov Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Rabin Medical Center | P2 | B · 62 |
| Carboplatin | Guangdong Association of Clinical Trials | P3 | BBB |
| Cyclophosphamide | Anusha Kalbasi | P2 | BBB |
| Cis-Diamminedichloroplatinum Ii | Guangdong Association of Clinical Trials | P3 | BB |
| Nivolumab | Emory University | P3 | BB |
| Etoposide | Guangdong Association of Clinical Trials | P3 | BB |
| Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Osimertinib | Shanghai Chest Hospital | P2 | BB |
| Gefitinib | Fujian Cancer Hospital | P3 | BB |
+42 more in the Lung Adenocarcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Lung Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-lung-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →